Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

This study has been completed.

Study NCT00057811 Information provided by National Cancer Institute (NCI)

First Received: April 7, 2003 Last Updated: November 20, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	October 2009 (Final data collection date for primary outcome measure)

Publications:

Goldman S, Lynch J, Harrison L, et al.: Preliminary results of the addition of rasburicase to the reduction cycle and rituximab to the induction and consolidation cycles of FAB group C chemotherapy in children and adolescents with advanced stage (bone marrow ±CNS) mature B-cell non-Hodgkin lymphoma (B-NHL): A Children's Oncology Group report . [Abstract] Blood 114 (22): A-104, 2009.

Cairo MS, Lynch J, Harrison L, et al.: Safety, efficacy and rituximab levels following chemoimmunotherapy (rituximab + FAB chemotherapy) in children and adolescents with mature B-cell Non-Hodgkin lymphoma (B-NHL): a Children's Oncology Group report. [Abstract] Blood 112 (11): A-838, 2008.